Watch IDYA. Know when insiders buy.
One email the day a filing lands. Free.
IDYA
IDEAYA Biosciences, Inc.
38.61
+0.88 +2.33%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · shorts 57
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.7BP/E —DIV YIELD —FCF YIELD -3.06%REV TTM $234.1MNET INCOME −$175MNET CASH —52W 25.67 – 42.48SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $8.9M | — | — | −$122.3M | −$112.5M | — | -1.22 | −$88.2M | $866K | −$89.1M | Aug 4 |
| Q1 2026 · Mar 31 | $6.6M | — | — | −$108.5M | −$98.5M | — | -1.11 | −$75.2M | $967K | −$76.1M | Aug 4 |
| Q4 2025 · Dec 31 | $10.9M | +55.4% | — | −$94.6M | −$83.3M | — | -0.94 | −$90.5M | $333K | −$90.8M | May 5 |
| Q3 2025 · Sep 30 | $207.8M | — | — | $108.5M | $119.2M | — | 1.33 | $142.2M | $42K | $142.2M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$88.8M | −$77.5M | — | -0.88 | −$62.5M | $663K | −$63.1M | Aug 4 |
| Q1 2025 · Mar 31 | — | — | — | −$84.4M | −$72.2M | — | -0.82 | −$60.3M | $1.3M | −$61.7M | May 5 |
| Q4 2024 · Dec 31derived | $7M | +78.5% | — | −$144.1M | −$130.3M | — | -1.55 | −$121.7M | $1.1M | −$122.8M | Feb 17 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$66.9M | −$51.8M | — | -0.60 | −$49.2M | $457K | −$49.7M | Nov 4 |
| Q2 2024 · Jun 30 | $0 | — | — | −$64.9M | −$52.8M | — | -0.68 | −$32.9M | $973K | −$33.9M | Aug 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$51M | −$39.6M | — | -0.53 | −$43.8M | $1.3M | −$45.1M | May 6 |
| Q4 2023 · Dec 31derived | $3.9M | — | — | −$41.9M | −$34M | — | -0.52 | −$23.7M | $838K | −$24.6M | Feb 17 |
| Q3 2023 · Sep 30 | $8M | — | — | −$33.5M | −$27.4M | — | -0.46 | −$30.2M | $603K | −$30.8M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $218.7M | — | −$159.3M | −$113.7M | -52.0% | -1.28 | −$71.1M | $2.4M | −$73.5M | — | — |
| FY2024 · to Dec 31 | $7M | — | −$327M | −$274.5M | -3921.1% | -3.36 | −$247.6M | $3.9M | −$251.4M | — | — |
| FY2023 · to Dec 31 | $23.4M | — | −$134.4M | −$113M | -483.0% | -1.96 | −$115.2M | $2.4M | −$117.6M | — | — |
| FY2022 · to Dec 31 | $50.9M | — | −$62.5M | −$58.7M | -115.2% | -1.42 | −$87.2M | $3.4M | −$90.6M | — | — |
| FY2021 · to Dec 31 | $27.9M | — | −$50.3M | −$49.8M | -178.1% | -1.41 | −$55.8M | $2.6M | −$58.4M | — | — |
| FY2020 · to Dec 31 | $19.5M | — | −$35.3M | −$34.5M | -176.6% | -1.40 | $55.5M | $493K | $55M | — | — |
Every number comes from IDEAYA Biosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.